Related Experiment Video
Updated: Jun 14, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Recent advances in chemotherapy for advanced gastric cancer in Japan
Masashi Fujii1, Mitsugu Kochi, Tadatoshi Takayama
1Department of Digestive Surgery, Nihon University School of Medicine, 1-8-13 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8309, Japan.
Abstract:
In the early 1990s, a combination of 5-fluorouracil (5-FU) and cisplatin was widely adopted to treat advanced gastric cancer; however, no survival advantage over single-agent 5-FU was confirmed by the results of randomized trials conducted over a long period. Recently developed agents such as irinotecan, taxanes (docetaxel), and new oral fluorouracil (S-1) have yielded more promising results, with a response rate of over 50% and a median survival time of over 10 months in combination studies. These newer combination regimens were investigated in various randomized phase III studies to clarify if the newer-generation regimens provided a survival advantage over the older-generation regimens. Based on the findings of a large randomized study, S-1 has become standard in the adjuvant setting after D2 dissection curatively resected stage II and III gastric cancer. This article reviews the recent advances in gastric cancer chemotherapy, especially in Japan.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistent Cancers
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
